Jose Juan Ponce Lorenzo
The Breast Cancer Research Foundation
4 Papers
Jose Juan Ponce Lorenzo is an academic researcher from The Breast Cancer Research Foundation. The author has contributed to research in topics: Veliparib & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl,Joyce O'Shaughnessy,Michael Untch,William M. Sikov,Hope S. Rugo,Mark D. McKee,Jens Huober,Mehra Golshan,Gunter von Minckwitz,David Maag,Danielle Sullivan,Norman Wolmark,Kristi McIntyre,Jose Juan Ponce Lorenzo,Otto Metzger Filho,Priya Rastogi,W. Fraser Symmans,Xuan Liu,Charles E. Geyer +18 more
TL;DR: The proportion of patients who achieved a pathological complete response in breast and lymph nodes as determined by site pathologists following completion of neoadjuvant therapy was higher in the paclitaxel, carboplatin, and veliparib group than in patients receiving pac litaxel alone.
682
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
CE Geyer,William M. Sikov,Jens Huober,Hope S. Rugo,Norman Wolmark,Joyce O'Shaughnessy,David Maag,Michael Untch,Mehra Golshan,Jose Juan Ponce Lorenzo,Otto Metzger,Martin Dunbar,W. Fraser Symmans,PS Rastogi,J. Sohn,Robyn R. Young,Gail S. Wright,C. Harkness,Kristi McIntyre,Denise A. Yardley,Sibylle Loibl +20 more
TL;DR: The BrighTNess trial as discussed by the authors showed that the addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC).
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
Charles E. Geyer,Joyce O'Shaughnessy,Michael Untch,William M. Sikov,Hope S. Rugo,Mark D. McKee,Jens Huober,Mehra Golshan,Vincent L. Giranda,Gunter von Minckwitz,David Maag,Danielle Sullivan,Norman Wolmark,Kristi McIntyre,Jose Juan Ponce Lorenzo,Otto Metzger Filho,Priya Rastogi,William Fraser Symmans,Xuan Liu,Sibylle Loibl +19 more
TL;DR: Primary response data from a phase 3 randomized, placebo-controlled study evaluating the addition of V + Cb or Cb to neoadjuvant paclitaxel (P) followed by doxorubicin + cyclophosphamide (AC) is presented.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Erica L. Mayer,Christian Fesl,Dominik Hlauschek,Laura García-Estévez,Harold J. Burstein,Nicholas Zdenkowski,Viktor Wette,Kathy D. Miller,Marija Balic,Ingrid A. Mayer,David Cameron,Eric P. Winer,Jose Juan Ponce Lorenzo,Diana Lake,Gunda Pristauz-Telsnigg,Tufia C. Haddad,Lois E. Shepherd,Hiroji Iwata,Matthew P. Goetz,Fatima Cardoso,Tiffany A. Traina,Danusha Sabanathan,Urs Breitenstein,Kerstin Ackerl,Otto Metzger Filho,Karin Zehetner,Kadine Solomon,Sarra El-Abed,Katherine P. Theall,Dongrui Ray Lu,Amylou C. Dueck,Michael Gnant,Angela DeMichele +32 more
TL;DR: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure and the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.